Role of PACAP in migraine headaches.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Brain : a journal of neurology

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/brain/awu014PMID 24549810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.

  2014cited by this paper
• Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients

  2013cited by this paper
• Role of VIP/PACAP in primary headaches

  2013cited by this paper
• Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system.

  2012cited by this paper
• Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice

  2012cited by this paper
• Kynurenines in the CNS: recent advances and new questions

  2012cited by this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cited by this paper
• PACAP38 induces migraine-like attacks in patients with migraine without aura.

  2009cited by this paper
• [Tension-type headache].

  2005cited by this paper
• Neuropeptide Localization in the ‘Migraine Generator’ Region of the Human Brainstem

  2001cited by this paper

• PACAP versus CGRP in migraine: From mouse models to clinical translation

  2025cites this paper
• Migraine Relief Through Botulinum Toxin Therapy: Exploring the Science Behind a Modern Treatment.

  2025cites this paper
• Exploring the Role of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and Kynurenine Pathway Dysregulation in Migraine Pathophysiology Among Women With Polycystic Ovary Syndrome (PCOS)

  2024cites this paper
• The pharmacotherapeutic management of episodic and chronic migraine with gepants

  2023cites this paper
• The functional heterogeneity of PACAP: Stress, learning, and pathology.

  2023cites this paper
• Risk Group

  2022cites this paper
• Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms

  2022cites this paper
• Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson’s disease focusing on correlations with motor symptoms

  2022cites this paper
• CGRP and CGRP-receptor as targets of migraine therapy: Brain Prize-2021.

  2021cites this paper
• Circulating PACAP peptide and PAC1R genotype as possible transdiagnostic biomarkers for anxiety disorders in women: a preliminary study

  2020cites this paper
• Investigation of migraine-related molecules in the activated trigeminovascular system

  2020cites this paper
• Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview

  2020cites this paper
• Migraine pathways and the identification of novel therapeutic targets

  2020cites this paper
• Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

  2020cites this paper
• Association of Intranasal and Neurogenic Dural Inflammation in Experimental Acute Rhinosinusitis

  2020cites this paper
• Therapeutic strategies that act on the peripheral nervous system in primary headache disorders

  2019cites this paper
• The therapeutic impact of new migraine discoveries.

  2019cites this paper
• Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies

  2019cites this paper
• Migraine and Cluster Headache: Differences and Similarities

  2019cites this paper
• The effect of psychiatric comorbidities and stress-coping strategies on perceived quality of life in migraine.

  2019cites this paper
• Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC

  2018cites this paper
• Treating status migrainosus in the emergency setting: what is the best strategy?

  2018cites this paper
• Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine

  2018cites this paper
• Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects.

  2017cites this paper
• Anatomy and Pathophysiology of Migraine

  2017cites this paper
• 11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches

  2017cites this paper
• Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects.

  2017cites this paper
• PACAP as a Potential Biomarker: Alterations of PACAP Levels in Human Physiological and Pathological Conditions

  2016cites this paper
• Release of PACAP-38 in episodic cluster headache patients – an exploratory study

  2016cites this paper
• CGRP antagonists and antibodies for the treatment of migraine

  2015cites this paper
• Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety

  2015cites this paper
• Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine.

  2015cites this paper
• Migraine and neuropeptides.

  2015cites this paper
• Drug safety and tolerability in prophylactic migraine treatment

  2015cites this paper
• Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design.

  2015cites this paper
• Drug safety in acute migraine treatment

  2015cites this paper
• Biochemistry of Primary Headaches

  2015cites this paper
• Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update

  2015cites this paper